Now Playing:
Up Next:
Take CE/CME Test
COVID-19, Vaccines, Viral Infections, Respiratory Infections CE/CME accredited

A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation. Close

Practical considerations for COVID-19 vaccination in the Middle East

Learning Objectives

After watching this activity, participants should be better able to:

  • Outline the benefits and risks associated with COVID-19 vaccines
  • Identify reasons for low COVID-19 vaccine uptake in the Middle East
  • Discuss approaches to increase COVID-19 vaccine uptake, with a focus on the role of healthcare workers

In this activity, experts in infectious diseases respond to questions from the primary care, respiratory and infectious diseases communities on the reasons for low COVID-19 vaccine uptake in the Middle East, the benefits and risks of vaccination, and how healthcare workers can help to improve acceptance of the COVID-19 vaccine.

This activity is jointly provided by USF Health and touchIME. read more

Target Audience

Infectious disease specialists, respiratory disease specialists and primary care physicians involved in the management of COVID-19 infection.


USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.


Dr Farhan Fazal has no interests/relationships or affiliations to disclose in relation to this activity.

Dr Nada Melhem has no interests/relationships or affiliations to disclose in relation to this activity.

Content reviewer

Sally F. Alrabaa, MD, has no financial interests/relationships or affiliations in relation to this activity.

Touch Medical Directors

Sola Neunie and Samantha Waite have no financial interests/relationships or affiliations in relation to this activity.

USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

Requirements for Successful Completion

In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

If you have questions regarding credit please contact



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (

Advanced Practice Providers

Physician Assistants may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

Date of original release: 30 May 2023. Date credits expire: 30 May 2024.

If you have any questions regarding credit please contact

This activity is CE/CME accredited

To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

Claim Credit

Topics covered in this activity

COVID-19 / Vaccines / Viral Infections / Respiratory Infections
  • 1000+ topical and insightful peer-reviewed journal articles
  • 100+ hours of bite-sized congress highlights
  • 9 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • + Concise email updates and newsletters so you never miss out
Register For Free Now
Claim Credit
Practical considerations for COVID-19 vaccination in the Middle East
1.0 CE/CME credit

Question 1/4
A 50-year-old visitor to your clinic has told you they have not received the COVID-19 vaccine as they know someone who had a heart attack after having the vaccine, and they are concerned about the side effects. What would you tell them about the evidence for the risk of CV events following COVID-19 vaccination?

CV, cardiovascular.

Side effects are mostly mild following COVID-19 vaccination and include headache, nausea, fever, fatigue and injection-site reactions.1,2 While there have been reports of CV events, including myocarditis, no causal relationship has been established.3 However, COVID-19 infection has been demonstrated to be associated with an increased risk of composite CV outcomes, including CV death, acute heart failure, myocardial infarction or pulmonary embolism,4 and so the benefits of vaccination outweigh the risks.3


CV, cardiovascular.


  1. Almohaya AM, et al. Vaccine. 2022;40:477–82.
  2. Abdullah RY, et al. NSC Nursing. 2022;2:1–22.
  3. Hana D, et al. Curr Probl Cardiol. 2022;47:101077.
  4. Tereshchenko LG, et al. Am J Cardiol. 2022;179:102–9.
Question 2/4
A parent tells you that their 11-year-old child has not been vaccinated against COVID-19, but that they have already had the infection. They only had mild symptoms and the parent is not convinced of the need to vaccinate their child. What would you tell them to encourage them to vaccinate their child?

While COVID-19 infection is mostly mild in children, some may still experience severe disease, particularly those who have underlying health conditions. Children may also be at risk of long-term complications from COVID-19, and therefore vaccination is advised to help prevent infection. Vaccinating children is important to help reduce community transmission and to avoid exclusion from daily activities, such as attending school.


Zimmermann P, et al. Arch Dis Child. 2022;107:e1.

Question 3/4
What strategy can be used by HCWs to address misinformation and improve public understanding of COVID-19 vaccination?

HCW, healthcare worker.

Misinformation spread by social media has led to misconceptions about the vaccine in terms of safety and efficacy, and even conspiracy theories.1 Effective engagement with the public to inform expectations is needed to help improve public trust in the vaccine.2 HCWs play a key role in public acceptance of the vaccine, and should be encouraged to help support vaccine uptake.3


HCW, healthcare worker.


  1. Al Naam YA, et al. Public Health Pract (Oxf). 2022;3:100258.
  2. Schoch-Spana M, et al. Vaccine. 2021;39:6004–12.
  3. Thomson A, Watson M. Vaccine. 2016;34:1989–92.
Question 4/4
What would you tell someone who is immunocompromised and concerned about their eligibility for the COVID-19 vaccine?

People who are immunocompromised, including people living with HIV or organ transplant recipients, are at an increased risk of severe disease and death after COVID-19 infection.1,2 Clinical data have shown that the response to the vaccines may be lower in people who are immunocompromised, although response can be improved with additional doses, so receiving the full course of vaccinations and available booster doses is important.1,2


  1. Galmiche S, et al. Clin Microbiol Infect. 2022;28:163–77.
  2. Lee ARYB, et al. BMJ. 2022;376:e068632.
Back to Activity
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72